Literature DB >> 22863577

Gout: why is this curable disease so seldom cured?

Michael Doherty1, Tim L Jansen, George Nuki, Eliseo Pascual, Fernando Perez-Ruiz, Leonardo Punzi, Alexander K So, Thomas Bardin.   

Abstract

Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood. One of the treatment objectives in current guidelines is 'cure'. However, audits show that only a minority of patients with gout receive adequate advice and treatment. Suboptimal care and outcomes reflect inappropriately negative perceptions of the disease, both in patients and providers. Historically, gout has been portrayed as a benign and even comical condition that is self-inflicted through overeating and alcohol excess. Doctors often focus on managing acute attacks rather than viewing gout as a chronic progressive crystal deposition disease. Urate-lowering treatment is underprescribed and often underdosed. Appropriate education of patients and doctors, catalysed by recent introduction of new urate-lowering treatments after many years with no drug development in the field, may help to overcome these barriers and improve management of this easily diagnosed and curable form of potentially severe arthritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863577     DOI: 10.1136/annrheumdis-2012-201687

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  85 in total

1.  Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

Authors:  Ted R Mikuls; T Craig Cheetham; Gerald D Levy; Nazia Rashid; Artak Kerimian; Kimberly J Low; Brian W Coburn; David T Redden; Kenneth G Saag; P Jeffrey Foster; Lang Chen; Jeffrey R Curtis
Journal:  Am J Med       Date:  2018-11-29       Impact factor: 4.965

Review 2.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

3.  New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome.

Authors:  Tim L Jansen; Dianne Berendsen; Tania O Crisan; Maartje C P Cleophas; Mirian C H Janssen; Leo A B Joosten
Journal:  Clin Rheumatol       Date:  2014-04-24       Impact factor: 2.980

4.  Gout: cartoonized and bagatellized and still left untreated. Time to change.

Authors:  Tim L Jansen
Journal:  Clin Rheumatol       Date:  2015-06-07       Impact factor: 2.980

5.  Gout: Risk of premature death in gout unchanged for years.

Authors:  Chang-Fu Kuo; Shue-Fen Luo
Journal:  Nat Rev Rheumatol       Date:  2017-03-02       Impact factor: 20.543

6.  Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?

Authors:  Matthew J Coleshill; Eindra Aung; Jane E Carland; Kate Faasse; Sophie Stocker; Richard O Day
Journal:  Ther Innov Regul Sci       Date:  2020-07-13       Impact factor: 1.778

Review 7.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

8.  Rheumatology meets radiology in the hot soup of Gutta.

Authors:  Tim L Jansen
Journal:  Arthritis Res Ther       Date:  2012-12-19       Impact factor: 5.156

9.  New ACR guidelines for gout management hold some surprises.

Authors:  Thomas Bardin; Pascal Richette
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

10.  Severe Carpal Tunnel Syndrome Caused by Gouty Tophi Diagnosed by Dual Energy Computed Tomography: Case Report.

Authors:  Yan Ge; Fen Li; Jinwei Chen; Jing Tian
Journal:  Arch Rheumatol       Date:  2016-05-17       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.